A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy
Latest Information Update: 14 May 2024
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms ARTS-DN
- Sponsors Bayer; Bayer HealthCare
- 10 May 2024 According to an Bayer media release, the company will present Kerendia data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), taking place May 11-14, 2024 in Lisbon, Portugal.
- 16 Jan 2023 Results published in the Journal of Hypertension
- 04 Oct 2019 Population pharmacokinetics and pharmacodynamics (PD) analysis for efficacy and safety markers based on data from two clinical phase IIb studies ARTS-DN (NCT01874431) and ARTS DN Japan (NCT01968668); results published in the Clinical Pharmacokinetics